RxDoctor Payments Data

Melissa Lee, MD

Internal Medicine · Southampton, PANPI 1639140122

Payments from drug & device makers

$2,285in general payments, 2019–2025

Across 136 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$454
  • Amgen$211
  • Lilly USA, LLC$205
  • AstraZeneca$189
  • Daiichi Sankyo Inc.$159
  • Boehringer Ingelheim$127
  • plus $940 from 24 others

What the payments were for

  • Food & beverage$2,285100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,285 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$136,425
Medicare patients
321
Services billed
1,471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin103$105,113
MounjaroTirzepatide57$65,750
TrulicityDulaglutide38$55,421
OzempicSemaglutide28$42,839
EliquisApixaban37$27,445
JanuviaSitagliptin Phosphate19$17,749
FarxigaDapagliflozin Propanediol18$13,042
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,732
Incruse ElliptaUmeclidinium Bromide16$7,295
Atorvastatin Calcium345$4,929
Rosuvastatin Calcium199$2,943
Levothyroxine Sodium218$2,909
Metoprolol Succinate150$2,541
Losartan Potassium163$2,366
Venlafaxine Hcl ErVenlafaxine Hcl17$2,352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$205$121,17195 claims
Boehringer IngelheimJardiance$127$105,113103 claims
Novo NordiskOzempic$454$42,83928 claims
PfizerEliquis$84$27,44537 claims
MerckJanuvia$81$17,74919 claims
GSKTrelegy Ellipta, Incruse Ellipta$80$16,02730 claims
AstraZenecaFarxiga$189$13,04218 claims
AbbVieSynthroid$68$2,24545 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Southampton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →